Prevacid Solutab Tablet, Orally Disintegrating, Delayed Release
Product Images NDC 64764-543

7 FDA label images from Takeda Pharmaceuticals America, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Prevacid Solutab (NDC 64764-543). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Prevacid 01)

Chemical Structure (Prevacid 01)
Chemical structure of lansoprazole, the active ingredient in Prevacid SoluTab, showing the molecular arrangement of atoms including benzene rings, nitrogen, sulfur, oxygen, and fluorine components.*
FDA Label Image

Figure 1 (Prevacid 02)

Figure 1 (Prevacid 02)
A line chart showing the mean severity of day heartburn by study day for evaluable patients, comparing placebo, lansoprazole 15 mg QD, and lansoprazole 30 mg QD groups. The x-axis represents days from the start of treatment, and the y-axis shows mean severity scored from 0 (none) to 3 (severe). The graph indicates decreasing heartburn severity over time in lansoprazole groups compared to placebo.*
FDA Label Image

Figure 2 (Prevacid 03)

Figure 2 (Prevacid 03)
A line graph depicting the mean severity of night heartburn over time in days from the start of treatment. The graph compares placebo, lansoprazole 15 mg once daily, and lansoprazole 30 mg once daily, showing changes in heartburn severity on a scale from 0 (none) to 3 (severe) for evaluable patients in a study.*
FDA Label Image

Prevacid Lansoprazole Delayed-release Capsules 15 mg Bottle Label (Prevacid 04)

Prevacid Lansoprazole Delayed-release Capsules 15 mg Bottle Label (Prevacid 04)
Label for Prevacid capsules containing 15 mg lansoprazole in delayed-release oral capsule form. The label displays the NDC 64764-541-30, indicating a package of 30 capsules, distributed by Takeda Pharmaceuticals America, Inc. It includes storage instructions, a barcode, and a warning to dispense the Medication Guide with each patient.*
FDA Label Image

Prevacid Lansoprazole Delayed-release Capsules 30 mgl Bottle Label (Prevacid 05)

Prevacid Lansoprazole Delayed-release Capsules 30 mgl Bottle Label (Prevacid 05)
Label for Prevacid lansoprazole delayed-release capsules, 30 mg strength. The label states the product contains 100 capsules and includes storage instructions, dosage directions referencing the package insert, and distributor information for Takeda Pharmaceuticals America, Inc., Lexington, MA. The label features a barcode, NDC 64764-046-13, and a caution to dispense the accompanying Medication Guide to each patient.*
FDA Label Image

Prevacid Lansoprazole Delayed-release Orally Disintegrating Tablets 15 mg Blister Carton Label (Prevacid 06)

Prevacid Lansoprazole Delayed-release Orally Disintegrating Tablets 15 mg Blister Carton Label (Prevacid 06)
Packaging label for Prevacid SoluTab Lansoprazole 15 mg delayed-release orally disintegrating tablets by Takeda Pharmaceuticals America, Inc. The label features the product name, strength, and dosage form. It indicates a package size of 100 tablets, containing 10 packs of 10 tablets each. The label also highlights that the package is not child-resistant and includes medication guide dispensing instructions.*
FDA Label Image

Prevacid Lansoprazole Delayed-release Orally Disintegrating Tablets 30 mg Blister Carton Label (Prevacid 07)

Prevacid Lansoprazole Delayed-release Orally Disintegrating Tablets 30 mg Blister Carton Label (Prevacid 07)
Label for Prevacid SoluTab lansoprazole 30 mg delayed-release orally disintegrating tablets by Takeda Pharmaceuticals America, Inc. The package contains 100 tablets in 10 packs of 10 tablets each. The label includes warnings that the package is not child-resistant and advises dispensing the enclosed Medication Guide to patients. The design features the product name prominently with a depiction of a pink, round tablet marked with '30'.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.